Curiosis

큐리오시스 · 494120

Information Technology Components · KOSDAQ

Small-cap

Market cap US$165.6M (₩228.5B)

Overview

Curiosis makes laboratory automation equipment, instruments that let scientists observe living cells growing inside incubators and separate specific cells or blood components without manual handling.

Its products are used in life-science research, drug development, diagnostics, and the production of cell-based therapies. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company designs and manufactures its products in-house, with its live-cell imaging system, the Celloger® series, serving as its primary revenue-driving product line.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$5.3M
Operating profit · FY2025
−US$5.5M
Net income · FY2025
−US$5.7M

Revenue

  • FY2025US$5.3M

Operating profit

  • FY2025−US$5.5M

Net income

  • FY2025−US$5.7M

Key ratios (FY2025)

ROE
-27.9%
Debt/Eq
21.4%
Op. margin
-103.0%
Net margin
-107.7%
Rev. YoY
N/A (see filing)

Why it matters

Curiosis has received recognition from Korea's Ministry of Trade, Industry and Energy, which designated the Celloger® as a 'World Class Product', a formal Korean government certification for globally competitive exports.

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.